Boehringer Ingelheim USA Corporation

Inventage Lab collaborates with Boehringer Ingelheim to develop long-acting injectable formulations for peptide-based drug candidates using its IVL-DrugFluidic platform, aiming for sustained release and minimized side effects. The partnership may expand to include joint clinical development, manufacturing, and commercial supply agreements.

The EASi-KIDNEY trial will assess if vicadrostat (BI 690517) improves CKD outcomes when combined with existing treatments. Running in 15-20 countries with 11,000 participants, it aims to determine if vicadrostat and empagliflozin reduce kidney disease progression, heart failure hospitalization, or cardiovascular death compared to empagliflozin alone. The trial uses Protas's Cantata platform for management and expects results by 2028/2029.

Novartis' Kisqali gets FDA approval for early-stage breast cancer; GSK's vaccines for RSV and shingles co-administered effectively; Novo Nordisk partners with NanoVation for genetic therapies; AstraZeneca's Mene Pangalos joins Omega Funds; Serán Biosciences secures $200M for new facility; Boehringer Ingelheim's nerandomilast shows success in Phase 3 IPF trial.

PD-1 inhibition with pembrolizumab before and after surgery significantly improves 5-year overall survival (86.6% vs 81.7%) in high-risk early triple-negative breast cancer, according to KEYNOTE-522 trial results.

Boehringer Ingelheim's nerandomilast met primary endpoint in Phase III FIBRONEER-IPF study, significantly improving lung function in IPF patients. The drug targets PDE4B enzyme to exert anti-fibrotic and anti-inflammatory effects. Boehringer plans to use study results for FDA and global regulatory submissions, with full data expected in H1 2025.

Phase 3 FIBRONEER-IPF trial met primary endpoint with nerandomilast in adults with IPF, showing absolute change in FVC. Boehringer Ingelheim plans to submit a new drug application to the FDA and present full findings in early 2025.

Boehringer Ingelheim seeks approval for nerandomilast after Phase III trial in idiopathic pulmonary fibrosis met primary endpoint. The trial, FIBRONEER-IPF, improved forced vital capacity after 52 weeks. Nerandomilast, a PDE4B inhibitor, received breakthrough therapy designation in 2022 and is also being tested in progressive fibrosing interstitial lung diseases.

Boehringer Ingelheim's nerandomilast met primary endpoint in phase 3 trial for idiopathic pulmonary fibrosis (IPF), marking the first successful IPF phase-3 trial in a decade. The oral drug, a preferential inhibitor of phosphodiesterase 4B, received FDA breakthrough therapy designation in 2022. Boehringer plans to submit a new drug application to the FDA and other regulators based on these positive results.

The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.